




PHARMACEUTICAL 2020

Integrated
BioPharma, Inc.

INTEGRATED BIOPHARMA INC
Rank 228 of 358





RealRate

PHARMACEUTICAL 2020

INTEGRATED BIOPHARMA INC Rank 228 of 358

Integrated
BioPharma, Inc.

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 211% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 219% points.

The company's Economic Capital Ratio, given in the ranking table, is 26%, being 10% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	14,079
Cost of Goods Sold	43,755
Intangible Assets	0
Liabilities, Current	12,353
Liabilities, Non-Current	5,544
Other Assets	3,933
Other Compr. Net Income	0
Other Expenses	354
Other Liabilities	0
Other Net Income	-662
Other Revenues	49,977
Property and Equipment	1,778
Research and Development	0
Selling, General and Administrative Expense	3,518

Output Variable	Value in 1000 USD
Assets	19,790
Liabilities	17,897
Expenses	47,627
Revenues	49,977
Stockholders Equity	1,893
Net Income	1,688
Comprehensive Net Income	1,688
Economic Capital Ratio	26%